ejpmr, 2016,3(4), 441-449

SJIF Impact Factor 3.628

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

Review Article

ISSN 2394-3211

EJPMR

MOLECULAR INSIGHTS INTO HEPATOCELLULAR CARCINOMA WITH BIOMARKER IDENTIFICATION: FROM BIRTH TO TREATMENT

Tanveer Ahmed Khan*[1], Baseer Ahmed Khan[2] and Lubna Shakir[1]

[1]Hajvery University, Lahore-Pakistan.
[2]Department of Biotechnology, Bahauddin Zakaria University, Multan-Pakistan.

***Corresponding Author: Tanveer Ahmed Khan**
Hajvery University, Lahore-Pakistan.

Article Received on 22/02/2016 **Article Revised on 13/03/2016** **Article Accepted on 03/04/2016**

ABSTRACT

Hepatocellular carcinoma is a complex cancer and it is usually diagnosed at advanced stage with several genomic alterations. There are several genomic pathways responsible in tumor development. These include Endothelial and Fibroblast Growth Factor-β Pathways, JAK/STAT Pathway, Mitogen-Activated Protein Kinase Pathway, p53 Pathway, pRb Pathway, Stress Response Signaling and Wnt/β-Catenin Pathway. Biomarker identification is an important tool for diagnosis of hepatocellular carcinoma. Several approaches were tested to treat hepatocellular carcinoma but the drug sorafenib showed life improvement benefits. However, to overcome the genetic abnormalities in hepatocellular carcinoma, several molecular target therapies were applied. These target therapies are Anti-EGFR Agents, Inhibitors of angiogenesis, PI3K/Akt/mTOR Inhibitors and others. Future research is required to identify innovative compounds and new therapeutic strategies to treat and cure hepatocellular carcinoma.

KEYWORDS: Cancer, Gene, Hepatocellular carcinoma, Tumor,

INTRODUCTION

Hepatocellular carcinoma (HCC) is a standout amongst the most widely recognized malignancies around the world, with the dominant part of cases coming about because of steady contamination with hepatitis B infection (HBV) or hepatitis C infection (HCV). Specifically, chronic HBV disease is a prevalent danger variable for HCC in Asia and Africa.[1] Hepatocellular carcinoma may present with yellow skin bloating from abdominal fluid, blood coagulation abnormalities, appetite loss, and unexpected weight reduction, epigastric pain, nausea, emesis or fatigue. The main risk factors for hepatocellular carcinoma are; Alcoholism, Hepatitis B, Hepatitis D, Hepatitis C (25% of causes globally), Aflatoxin, Liver Cirrhosis, Nonalcoholic steatohepatitis, Hemochromatosis, Wilson's disease, Type2 diabetes mellitus (probably aided by obesity). Hepatitis B endemic countries like China, the predominant cause of Hepatocellular Carcinoma (HCC) will be Hepatitis B.[2] The risk of HCC in type 2 diabetics is greater from 2.5[3] to 7.1[4] times the non-diabetic risk, however, it depends on the duration of diabetes and treatment protocol. Another important factor that may increase this risk is circulating insulin concentration.[3],[2] In spite of the fact that hepatocellular carcinoma most regularly influences grown-ups, youngsters who are influenced with biliary atresia, infantile cholestasis, glycogen-storage disease, and other cirrhotic infections of the liver are inclined to developing hepatocellular carcinoma. Children and adolescents are unrealistic to have chronic liver disease; then again, in the event that they experience the ill effects of intrinsic liver issue, this builds the possibility of developing hepatocellular carcinoma.

Diagnosis

Patients at risk of HCC, which include cirrhosis due to HBV, HCV, alcohol, genetic hemochromatosis, non-alcoholic steatohepatitis, primary biliary cirrhosis, alpha1-antitrypsin deficiency, other causes of cirrhosis, and HBV carriers without cirrhosis, should be monitored every six months with alpha-fetoprotein (AFP) and liver ultrasound (US) examination aimed at the early detection of HCC. The most commonly used routine periodic surveillance tests of individuals with HCC are AFP and hepatic US, which must be performed half a year in terms of doubling time of tumor progression.[5]

Staging

Vital components that guide treatment incorporate size, spread (stage), contribution of liver vessels, vicinity of a tumor case, vicinity of extra-hepatic metastases, vicinity of daughter knobs, vascularity of the tumor, MRI is the best imaging technique to recognize the vicinity of a tumor case. As to HCC, because of the previously stated heterogeneity, arranging frameworks and/or prognostic scores must record for the tumor weight, accordingly demonstrating the extraordinary obliged attributes of such markers. Therefore, in spite of the fact that various arranging frameworks for HCC have been proposed and created, there is as of now no all-around appropriate system of staging.[6]

GENETIC PATHWAYS AND MOLECULAR MECHANISMS OF HEPATOCELLULAR CARCINOMA

The pathophysiology of HCC is not clearly understood, but rather liver dysfunction, particularly cirrhosis, is an inclining condition. Following pathways are being discussed broadly to distinguish potential biomarkers and molecular targets.

Endothelial and Fibroblast Growth Factor-β Pathways

The molecular flow of HCC can likewise be impacted by proteins and cell variables of other signaling pathways. For instance, vascular endothelial growth factor and fibroblast growth factor assume imperative parts in HCC development.[7] It was accounted for as of late that inflammation is inalienably connected with disease and various cytokines are included in advancing HCC advancement and proliferation, particularly amid contamination with hepatitis viruses.[8] Specifically, Th2 cytokines are prompted and Th1 cytokines diminished in metastases. Along these lines, adjusting the outflow of cytokines and the utilization of inhibitors of provocative cytokines may be discriminating in easing HCC spread.

JAK/STAT Pathway

The JAK-STAT signaling pathway sends information from chemical signals that are outside the cell into gene promoters on the Deoxyribose Nucleic acid in the cell nucleus. This causes transcription of DNA in the cell. This pathway consists of three main components: a receptor; Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT).[9] Transcription factors are activated through phosphorylation of tyrosine by JAKs. These activated factors (STATs) start suppressors' transcription of cytokine signaling (SOCS) genes. SOCS proteins connect to phosphorylated JAKs and their receptors to inhibit this pathway, thereby anticipating over activation of cytokine-stimulated cells.[10] Thus, SOCS play a role in the negative feedback loop in the JAK/ STAT circuitry. Two other families of STAT inhibitors include the protein inhibitors of activated STATs and the SH2-containing proteins.[11] JAK incitement of STATs actuates cell multiplication, migration, separation, and apoptosis, and deregulation of inhibitors prompts various diseases of humans, including cancer.[9] Deactivation of SOCS-1 and SSI-1, a JAK-tying protein, in HCC have been reported,[10] as has the universal initiation of the JAK/STAT pathway.[12]

Mitogen-Activated Protein Kinase Pathway

Mitogen-activated protein kinases (MAPK) are protein kinases that are specific to the number of amino acids that include serine, threonine, and tyrosine. MAPKs belong to the CMGC (CDK/MAPK/GSK3/CLK) kinase group. These are involved in directing cellular responses to a various stimuli, such as pro-inflammatory cytokines mitogens, osmotic stress, and heat shock. They are responsible in regulation of cell functions such as cell proliferation, gene expression, differentiation and apoptosis. These kinases activity is based upon dual phosphorylation of T and Y residues located in their activation loop. MAPKs were ensnared in various cell procedures, for example, cell survival, separation, adhesion, and multiplication.[13],[14] Proteins of HBV, HCV, and hepatitis E infection tweak MAPK targeting so as to motion numerous progressions along the signaling pathway.[15] For example, HCV E2 protein enacts the MAPK pathway in human hepatoma Huh-7 cells and advances cell proliferation.[16] In HCC of human, the levels of expression of Spred protein (Sprouty-related protein with Ena/vasodilator) are deregulated.[17] Forced articulation of Spred brought about hindrance of ERK initiation both in vivo and in vitro, bringing about diminished expansion of cancerous cells and low discharge of matrix metalloproteinases 2 and 9. This investigation shows direct connection of MAPK-ERK pathway actuation and HCC, proposing that Spred could serve as a therapeutic focus for human HCC.

p53 Pathway

The tumor suppressor TP53 gene is inactivated by a single point mutation in about a large portion of all human tumors.[18] In the remaining malignancies, p53 is communicated at ordinary levels however the p53 signaling that prompts cell cycle capture and consequent apoptosis is deficient. Loss of p53 capacity additionally sharpens cells to checkpoint signals.[19] when all is said in done, cell levels of p53 are low; be that as it may, in light of intracellular and extracellular signals during stress, p53 expression is up-regulated. The operators that damage DNA, for example, chemotherapeutic medications and ultraviolet or gamma irradiation, likewise initiate p53 by covalent change, including phosphorylation of the transactivation area and acetylation and phosphorylation of fundamental allosteric control locale by ataxia telangiectasia transformed and related kinases.[20] Several studies have reported that p53 transformations and inactivation assume a discriminating part in HCC. Subsequently, identification of mutant p53 in plasma serves as a potential biomarker for AFB1 presentation and vicinity of liver cancer. The oxidative stress under such conditions results in the improvement of cirrhosis with a 200-fold hazard for HCC.

pRb Pathway

The tumor silencer retinoblastoma protein pRb1 is a noteworthy cell boundary to malignancy development.[21] A connection between loss of pRB and absence of functional p53 was seen in ahead of schedule studies on human tumors.[22] Taken together with the way that few DNA tumor infections, for example, human papilloma infections, encode proteins that inactivate both pRB and p53, it has been proposed that loss of pRB results in p53-dependent apoptosis. The CDK inhibitors $p16_{INK4A}$, $p21_{(WAF1/CIP1)}$, and $p27_{Kip1}$ are freely influenced and an adjustment in the statement of one or a greater amount of these inhibitors adds to carcinogenesis in almost 90% of HCC cases.[23] $p16_{INK4A}$ is dominatingly inactivated amid

the early phases of hepatocarcinogenesis. The diminished p21 $_{(WAF1/CIP1)}$ expression, which is related basically with p53 gene mutation in HCCs, additionally adds to hepatocarcinogenesis. A few studies have shown that the pRb pathway is extremely upset in HCC patients.

Ras Pathway

Human ras proteins H-Ras, N-Ras, K-Ras4a, and K-Ras4B are little GTP-tying proteins that capacity as molecular changes to impact cell development, separation and apoptosis.[24] Single point transformations in codon 13 of H-ras, codon 12 of N-ras, and codon 61 of K-ras were initially seen in HCC created by different chemicals, for example, N-nitrosomorpholine, bleomycin, 1-nitropyrene, and methyl (acetoxymethyl) nitrosamine.[20,25-28] Ras connects with a downstream serine/threonine kinase Raf-1 prompting its actuation and downstream signaling, which incorporates initiation of MAPK kinases MEK1 and MEK2, to control multiplication and apoptosis.[29] Activation of Ras and articulation of Ras pathway proteins, for example, p21 were additionally reported in strong tumors,[30],[31] and in cell lines. The methodologies of restraining a few kinases and smothering Ras expression utilizing antisense RNA were effectively connected in cell line and in animal models.[32] It has been proposed that the Ras pathway is critical in HCC of mice yet not human HCC in view of the low change rate of Ras in humans.[33] However, in a late study, it was accounted for that RASSF1A and NORE1A, individuals from the RASSF group of Ras inhibitors, are inactivated in human HCC, exhibiting the part for Ras pathway in liver cancer.

Stress Response Signaling

Heat shock proteins (HSPs) are basic players in cell stress reaction. Under stress conditions, they experience phosphorylation and/or dephosphorylation. In a late study directed with 48 clinical subjects, HCC movement was observed to be connected with the lessening in serine phosphorylation of HSP27.[34] In another study with 146 clinical subjects, a few individuals from the HSP family were observed to be connected with the event of HCC,[35] recommending that HSPs are key players in HCC proliferation.

Wnt/β-Catenin Pathway

The Wnt signaling pathway is very preserved in transformative pathways included in homeostasis, cell multiplication, separation, motility, and apoptosis.[36] It is deregulated in various growths, incorporating HCC.[37] In many cases, either the inactivation of the tumor suppressor gene adenomatous polyposis coli or change of the proto-oncogene β - catenin and the enactment of Wnt signaling was noted. This pathway is included in HCC emerging from HBV/HCV contaminations and alcoholic cirrhosis of liver. This up-regulation of frizzled-7 and dephosphorylation of β - catenin is as often as possible found in HCC.[38] Therefore, focused on inactivation of Wnt pathway is a potential remedial focus for cancer. Changes in β - catenin do advance the enactment of Wnt/β - catenin signaling, however they keep its phosphorylation and ensuing debasement. Mutant protein ordinarily gathers in the nucleus, and its vicinity corresponds with low frequency of HCC.[39],[40] Furthermore, transformations in β - catenin emerge in HCC patients with expanded introduction to HCV infection[41] and aflatoxin.[42] Notwithstanding these changes in β - catenin, transformations in Axin 1 and Axin 2, negative controllers of Wnt pathway, were likewise seen in HCC.[43] Thus, Wnt/β - catenin pathway is a critical signaling pathway in HCC.

IDENTIFICATION OF BIOMARKERS AND MOLECULAR PROFILING

Molecular profiling of proteins, genes and different particles gives capable apparatuses to pick up knowledge into the molecular systems of fundamental carcinogenesis.[44] Such profiling permits us to comprehend the molecular life structures of ordinary cells and that of tumor cells.

Genomics Aberrations

HCC presentations gross genomic changes, including chromosomal mutations, CpG methylation, DNA revisions connected with HBV reconciliation, DNA hypomethylation, and, to a lesser degree, microsatellite flimsiness.[45]

Role of MicroRNAs in Hepatocarcinogenesis:

Identification of little, noncoding RNAs in the mid-1990s has prompted the improvement of another examination range of RNomics.[46] Several distinct classes of noncoding RNAs have been found in mammalian cells. These incorporate small interfering RNAs,[47] small nucleolar RNAs,[48] and microRNAs (miRNAs).[49] miRNAs are at first created by RNA polymerase II as primary precusor transcripts that frame a stem–loop structure and experience handling by a protein complex containing the RNase III enzyme Drosha and the twofold stranded RNAbinding protein Pasha in the core. These prepared precusors (pre-miRNAs) are then sent out into the cytoplasm by exportin-5, where they experience further handling by RNase III endonuclease Dicer. These mature miRNAs measuring 20 to 23 nucleotides long are consolidated into miRNA-prompted silencing complexes. These complexes then tie to flawed complementary sequences in the 3_ untranslated area of target mRNAs and contrarily manage gene expression either through mRNA drgradation or translational inhibition.[49] Recent studies have exhibited that modifications in miRNA genes lead to tumor development, and a few miRNAs that direct either the tumor suppression or advance tumor growth have been identified.[50] These miRNAs might be helpful to screen patients to recognize those with a high probability of developing metastases.

Gene Profiling

Collection of transformations and modifications in functional genes frequently brings about carcinogenesis.

HCC improvement and proliferation created by hereditary changes bringing about adjusted articulation of a large number of malignancy related genes can be measured by worldwide hereditary investigation. The expression of gene profiling of HCC has been utilized to explain hepatocarcinogenesis and to distinguish molecular components of fundamental complex clinical characteristics. Recognizable proof of phenotype-related gene profiling will have a noteworthy effect on the determination and administration of HCC.[51] Common advances used to study genomics incorporate correlative DNA (cDNA) microarrays to investigate worldwide gene expression, single nucleotide polymorphism genotyping to distinguish transformations that change the quality expression and unusual protein functions, ID of locales of chromosomal abnormalities, and DNA–protein communications. By and large, these genomic studies have given tremendous measures of data on both up-down regulation of genes, proposing that various cell procedures are influenced by HCC infection states.

Protein Profiling

The term proteome is utilized to allude to the whole arrangement of proteins encoded by the genome of an organism,[52] and proteomics is the investigation of the expression, structure, and capacity of proteins. Customarily, the investigation of protein profiles was performed utilizing two-dimensional gel electrophoresis (2D-GE),[53] a procedure in which proteins are isolated in the first measurement by their sub-atomic weight and in the second measurement by their isoelectric point. The proteins distinguished as one of a kind after examination in the middle of tumor and non-tumor tests are extracted and contemplated further utilizing mass spectrometry (MS) approaches.[54] 2D-GE is a basic and effective strategy to envision a huge number of proteins and identify their adjustments and post-translational alterations; then again, intergel variety, work escalation, and high cost are significant disadvantages. A critical development in a polyacrylamide gel electrophoresis–based methodology has been the fluorescent two-dimensional differential in-gel electrophoresis.[55] In this system, diverse specimens are prelabeled with fluorescent cyanine colors (Cy2, Cy3, or Cy5) that are coordinated to the mass and charge of proteins and coseparated on the same gel to overcome intergel variations.[56] Two-dimensional differential in-gel electrophoresis can yield more prominent exactness for evaluation than silver staining because of better affectability and element scope of fluorescent dyes.[57] New strategies are being applied to improve the affectability and ability to handle expansive scale proteomic studies. Such techniques incorporate lattice helped laser desorption/ionization time-of-flight (MALDI-TOF) MS,[58] surface-improved laser desorption/ionization (SELDI),110 stable isotope naming with amino acids in cell society, isotope-covered proclivity tag, and isobaric labels for relative and outright evaluation.

Metabolomics

Metabolomics is a department that intends to measure worldwide composition of metabolites and distinguish particular phenotypes of the tissue, organ, or organism. Because metabolic pathways are downstream of gene expression and protein combination, they may mirror the natural movement of a cell at practical level more accurately.[59] Various systems have been depicted to study metabolites. They incorporate direct infusion electrospray MS, nuclear magnetic resonance spectroscopy, Raman spectroscopy, gas and fluid chromatography, Fourier change infra-red spectroscopy.[60] When HBV-and HCV-related HCC tissues were analyzed utilizing proteomics, it was found that enoyl-CoA reductase was decreased in HBV and expanded in HCV associated HCC.[61] Over expression of stathmin 1 and multiplying cell nuclear antigen happened just in HBV, though hepatic aldolase B was supplanted by non-hepatic isoform An in HCV-contaminated tissues.[62] Up-regulation of apolipoprotein E, a protein that modifies β-catenin dispersion, was likewise reported for HCV-actuated HCC.[63] Similarly, fructose-bisphosphate aldolase B was down regulated, and proteins included in glucose digestion system and osmoregulation were additionally differentially communicated in HBV-related HCC.[64] Down-regulation of different metabolic compounds and cathepsin A was likewise reported. A late study demonstrated that the ubiquitin-conjugating catalyst E2C (Ube2c) was over expressed in human HCC at essentially larger amounts than in the relating noncancerous tissues. Patients with high Ube2c expression likewise indicated essentially lower disease free survival rates than those with low Ube2c expression.[65] Thus, Ube2c is a potential prognostic biomarker for HCC.

Role of Stem/Progenitor Cells in HCC

Throughout the years, it has been entrenched that both hepatocytes and cholangiocytes are equipped for repopulating liver tissue taking after injury.[66] Therefore, the idea of stem/ancestor cell presence in the liver did not increase much acknowledgment until the previous decade. Besides, developing evidence likewise showed that the ability to maintain tumor arrangement and development lives in a little extent of disease foundational microorganisms (CSCs).[67] In the early studies, embryonic stem cells from murine incipient organisms were indicated to separate into practical hepatocytes in vitro.[68] It was later demonstrated that murine and also human bone marrow–derived mesenchymal stem cells could separate into hepatocytes both in vitro and in vivo.[69] One of the most well-known liver stem cell is the oval cell. Oval cells express markers normal to hepatocytes and cholangiocytes, recommending that they are bipotential. Actually, they separate into hepatocytes and cholangiocytes in vitro under the suitable cultural conditions.[70] In alcoholic liver disease and HCV infection, oval cell numbers build and relate with the seriousness of the disease.[71] Further

studies with these progenitor cells may give knowledge to comprehend the molecular events that control liver cell separation and those that prompt tumor growth.

MOLECULAR TARGETED THERAPIES IN HEPATOCELLULAR CARCINOMA

In spite of late enhancements in surveillance projects and analytic instruments permitting recognizable proof of little suspicious nodules, just 30%-40% of patients with HCC are qualified for corrective treatments.[72] In all around chose patients, resection and liver transplantation give 5-year survival rates of 70% though neighborhood removal with radiofrequency achieves 50%.[72],[73] It is accepted that these medications change the normal history of the disease. Tumor relpase confuses 50% of the patients at 3 years, and none of the 14 RCTs distributed so far give an in number basis to set up a standard adjuvant therapy.[74]

Most studies have been led amid the most recent 5 years and focused on protein kinases, the significant medication focuses in oncology.[75] Agents are gathered by primary focuses on: (1) Anti-EGFR: erlotinib, cetuximab, gefitinib and lapatinib; (2) Anti-angiogenic specialists: cediranib, bevacizumab, sunitinib, vatalanib, sorafenib, and combinations; (3) mTOR inhibitors: termsirolimus, everolimus; (4) Other operators: IGFR1 inhibitors, cmet inhibitors and Wnt inhibitors.

Anti-EGFR Agents

Three tyrosine kinase inhibitors focusing on EGFR have been tried in HCC: erlotinib and gefitinib focusing on EGFR and lapatinib focusing on both EGFR and Her2/nu. Cetuximab, a monoclonal counter acting agent against EGFR, has likewise been evaluated. Erlotinib has indicated movement both in preclinical and clinical studies. The main report testing erlotinib at 150 mg every day in HCC included 38 patients with middle/progressed HCC (39% of which with extrahepatic metastases) and portrayed a low reaction rate (9%) and 6-month PFS in 32% of patients (12 of 38 patients).[76] The middle survival was 13 months, which can be clarified by the activity of the medication, additionally in light of the fact that the objective populace was not the same as the ordinary progressed HCC populace (42% of patients without basic liver sickness). In a moment study including 40 patients, the middle general survival was 25 weeks (95% CI: 18-42 weeks).[77] Gefitinib forestalled HCC advancement in exploratory models, yet a study in 31 patients reported amedian survival of 6.5 months, and the creators reasoned that the medication had no activity.[78] Although Her2/neu over expression and EGFR changes are phenomenal events in HCC, a double receptor bar lapatinib (EGFR and Her2) is being tried in trial models of HCC and early clinical trials.

Inhibitors of Angiogenesis

HCC is a famously hypervascular threat, even at right on time phases of the disease. Experimental studies exhibit that focusing on angiogenesis is of real significance in HCC. The fundamental compounds tried in clinical trials are monoclonal antibodies (bevacizumab) and small molecules (sunitinib, bivranib, vatalanib, sorafenib, cediranib). Bevacizumab is an adapted monoclonal immune response against VEGF sanction for the treatment of breast growth and liver metastasis of colorectal disease. The component of activity of this compound is dubious, in light of the fact that it may act by killing VEGF additionally normalizing the vasculature to recover the typical perfusion of tumors with abnormal vascularization. A stage I/II trial in 33 selected patients without entrance vein attack uncovered unassuming antitumoral movement (10% goal reaction) with a middle TTP of 6.5 months.[79] Of note is that two patients created major gastrointestinal bleeding, one of them prompting demise. In a French study including 30 patients, three patients likewise displayed draining complications.[80] Combinations of bevacizumab with chemotherapy (oxaliplatin, gemcitabine, capecitabine), get target reactions of 10%-20% with middle survivals of 9-10 months.[81],[82] A study in 27 patients that surveyed blend of bevacizumab with erlotinib reported a shockingly high middle survival of 15.5 months. Six patients indicated target reactions (20%). These fascinating informations should be affirmed inside broad randomized stage II studies, in light of the fact that it may mirror the synergistic action of the mix, additionally a determination predisposition because of the enrollment of patients in the badly characterized classification of "unresectable" HCC, or short follow-up. Two stage II studies have analyzed the security and viability of the multikinase inhibitor sunitinib in cutting edge HCC,[83],[84] a medication officially affirmed for renal cell carcinoma and gastrointestinal stromal tumors. Sunitinib represses VEGFR1 and VEGFR2, PDGFR, c-Kit, and FLt3, among different kinases. The main European/Asian study treated 37 patients with day by day measurements of 50 mg/day and reported one fractional reaction; 13 indicated stable disease.[83] Of note, nonetheless, was that four patients experienced treatment-related antagonistic occasions prompting passing because of gastrointestinal dying, encephalopathy, and hepatorenal disorder. The U.S. study treated 26 patients at 37.5 mg/day and demonstrated a middle PFS of 4.5 months, general survival of 11.6 months, and more reasonable reactions, albeit one passing because of draining was reported.[84] The more awful well-being profile related to this medication in HCC contrasted and different tumors—renal, gastrointestinal stromal tumor—focuses to the requirement for being mindful in the administration of extremely powerful antiangiogenic operators in patients with cirrhosis. Three antiangiogenic and multikinase specialists—brivanib, cediranib and vatalanib—are being tried as of now and information are enthusiastically awaited.

PI3K/Akt/mTOR Inhibitors

Roughly half of patients with HCC have enactment of the mTOR pathway as evaluated by

immunohistochemical investigation of phosphorylated S6.[84] This actuation may be the after effect of increased signaling because of over expression of ligands (i.e., EGF, IGF1, and IGF2) or may be because of changes in oncogenes (PI3KCA) or tumor suppressing genes (PTEN). Some of these patients have a synchronous initiation of Akt. Rapamycin is an inhibitor of mTOR action affirmed as immunosuppressant in liver transplantation. An enticing system is to utilize it as first-line antirejection treatment in the setting of liver transplantation for HCC, yet results of randomized studies are expected to support this procedure. Preclinical studies with different analogs of rapamycin (i.e., everolimus, temsirolimus) have demonstrated action as single operators in xenograft models, [84] and stage II studies are as of now testing these complexes alone or in combination with sorafenib.

IGFR1 and Other Molecular Agents

IGF signaling initiation has been applied in the pathogenesis of HCC.[85] Drugs hindering the receptor IGFR1, for example, the monoclonal counter acting agent A12, diminish tumor development and enhance survival of HCC xenografts, giving the basis to test them in clinical trials. Studies with little atoms and monoclonal antibodies against IGFR1 are continuous. So also, there is method of reasoning to test c-MET inhibitors. The Wnt pathway is actuated in no less than 30% of HCCs[86],[87] at the same time, tragically, there are not yet medicates accessible that successfully obstruct its enactment without noteworthy reactions. Molecular targets of this pathway incorporate Wnt ligands, Frizzled receptors, and the oncogene β-catenin. Preclinical studies have demonstrated movement with diverse exacerbates that are as of now tried. Likewise, there are dynamic medications hindering the proteasome actuation, however the outcomes for bortezomib, which is prescribed for different myeloma, are not promising. Telomerase, thought to be the key in tumor cell everlasting life, is a potential focus in HCC,[88] there are some progressing studies applying TERT vaccination. At long last, trials with medications hindering the Hedgehog pathway and histone deacetylase inhibitors are required to be tried in future.

Combination Therapies

Combination of molecular treatments is relied upon to enhance the result advantages effectively got with sorafenib, yet this is an exceptionally complex matter. There is a justification for blocking reciprocal pathways initiated in HCC. This is the situation with hostile to antiangiogenic operators and blockers of cell expansion, for example, EGFR, MET, and IGFR inhibitors. An option methodology is to join treatments repealing correlative intracellular signaling, for example, RAS or mTOR inhibitors with cell expansion inhibitors. Also, proapoptotic specialists may synergize with cell expansion inhibitors. Biomarkers of response and imperviousness to molecular treatments are expected to give further justification to combination treatments. A few systems of resistance portrayed in other strong tumors may additionally apply to HCC. For example, resistance to EGFR inhibitors is intervened by transformations in downstream oncogenes (RAS) or tumor silencers (PTEN) or central amplifications of MET. Essentially, resistance to mTOR inhibitors may be intervened by a negative circle actuating IGFR signaling. The complete understanding of these pathways and mechanisms will guide appropriate drug combinations.

REFERENCES

1. Miamen, A.G., H. Dong, and L.R. Roberts, Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver cancer, 2012; 1(3-4): p. 226-237.
2. Tanaka, M., et al., Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. Journal of epidemiology, 2011; 21(6): 401-416.
3. El–Serag, H.B., H. Hampel, and F. Javadi, The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical Gastroenterology and Hepatology, 2006; 4(3): 369-380.
4. Hassan, M.M., et al., Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer, 2010; 116(8): 1938-1946.
5. França, A.V.C., et al., Diagnosis, staging and treatment of hepatocellular carcinoma. Brazilian journal of medical and biological research, 2004; 37(11): 1689-1705.
6. Kinoshita, A., et al., Staging systems for hepatocellular carcinoma: Current status and future perspectives. World journal of hepatology, 2015; 7(3): 406.
7. Budhu, A., et al., Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell, 2006; 10(2): 99-111.
8. Schiffer, E., et al., Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology, 2005; 41(2): 307-314.
9. Yoshikawa, H., et al., SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nature Genetics, 2001; 28(1): 29-35.
10. Wormald, S. and D.J. Hilton, Inhibitors of Cytokine Signal Transduction. Journal of Biological Chemistry, 2003; 279(2): 821-824.
11. Nagai, H., et al., Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Letters, 2002; 186(1): 59-65.
12. Yasuda, E., et al., Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular

carcinoma. Biochemical and Biophysical Research Communications, 2005; 337(1): 337-342.
13. Wong, C.-H. and C. Yan Cheng, Mitogen-activated protein kinases, adherens junction dynamics, and spermatogenesis: A review of recent data. Developmental Biology, 2005; 286(1): 1-15.
14. Panteva, M., H. Korkaya, and S. Jameel, Hepatitis viruses and the MAPK pathway: is this a survival strategy? Virus Research, 2003; 92(2): 131-140.
15. Zhao, L., et al., Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors. Experimental Cell Research, 2005; 305(1): 23-32.
16. Yoshida, T., et al., Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene, 2006; 25(45): 6056-6066.
17. Satoh, T., et al., Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proceedings of the National Academy of Sciences, 1991; 88(8): 3314-3318.
18. Giaccia, A.J. and M.B. Kastan, The complexity of p53 modulation: emerging patterns from divergent signals. Genes & Development, 1998; 12(19): 2973-2983.
19. Hickman, E., The role of p53 and pRB in apoptosis and cancer. Current Opinion in Genetics & Development, 2002; 12(1): 60-66.
20. Li, H., et al., Low frequency of ras activation in 2-acetylaminofluorene- and 3′-methyl-4-(dimethylamino)azobenzene-induced rat hepatocellular carcinomas. Cancer Letters, 1991; 56(1): 17-24.
21. Dynlacht, B.D., et al., Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes & Development, 1994; 8(15): 1772-1786.
22. Hsia, C.C., et al., RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. J. Med. Virol., 1994; 44(1): 67-73.
23. Azechi, H., et al., Disruption of the p16/Cyclin D1/Retinoblastoma Protein Pathway in the Majority of Human Hepatocellular Carcinomas. Oncology, 2001; 60(4): 346-354.
24. Clark, G.J., et al., Differential antagonism of Ras biological activity by catalytic and Src homology domains of Ras GTPase activation protein. Proceedings of the National Academy of Sciences, 1993; 90(11): 4887-4891.
25. Challen, C., et al., Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. Journal of Hepatology, 1992; 14(2-3): 342-346.
26. Baba, M., et al., Ha-ras mutations in N-nitrosomorpholine-induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver. International Journal of Cancer, 1997; 72(5): 815-820.
27. Morrison, D.K. and R.E. Cutler, The complexity of Raf-1 regulation. Current Opinion in Cell Biology, 1997; 9(2): 174-179.
28. Bai, F., et al., Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice. Teratog. Carcinog. Mutagen., 2003; 23(S1): 161-170.
29. Nonomura, A., et al., Immunocytochemical study of ras oncogene product p21 in liver cirrhosis and hepatocellular carcinoma. Acta hepatologica Japonica, 1987; 28(1): 69-75.
30. Calvisi, D.F., et al., Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC. Gastroenterology, 2006; 130(4): 1117-1128.
31. Liao, Y., et al., Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA-in vitro and in vivo studies. Journal of Cancer Research and Clinical Oncology, 1997; 123(1): 25-33.
32. Grisham, J., Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis, 1997; 18(1): 59-81.
33. Luk, J.M., et al., Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics, 2006; 6(3): 1049-1057.
34. Yoshiji, H., et al., Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development. Oncology Reports, 2005.
35. Nelson, W.J., Convergence of Wnt, -Catenin, and Cadherin Pathways. Science, 2004; 303(5663): 1483-1487.
36. Merle, P., et al., Oncogenic role of the frizzled-7/β-catenin pathway in hepatocellular carcinoma. Journal of Hepatology, 2005; 43(5): 854-862.
37. Terris, B., et al., Close correlation between β-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene, 1999; 18(47): 6583-6588.
38. Hsu, H.-C., et al., β-Catenin Mutations Are Associated with a Subset of Low-Stage Hepatocellular Carcinoma Negative for Hepatitis B Virus and with Favorable Prognosis. The American Journal of Pathology, 2000; 157(3): 763-770.
39. Devereux, T.R., et al., CTNNB1 mutations and ?-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1. Mol. Carcinog., 2001; 31(2): 68-73.
40. Satoh, S., et al., AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genetics, 2000: 24(3): 245-250.
41. Taniguchi, K., et al., Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular

carcinomas and hepatoblastomas. Oncogene, 2002; 21(31): 4863-4871.
42. Colnot, S., et al., Liver-targeted disruption of Apc in mice activates -catenin signaling and leads to hepatocellular carcinomas. Proceedings of the National Academy of Sciences, 2004; 101(49): 17216-17221.
43. Wiman, K.G., Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ, 2006; 13(6): 921-926.
44. Thorgeirsson, S.S., J.-S. Lee, and J.W. Grisham, Functional genomics of hepatocellular carcinoma. Hepatology, 2006; 43(1): 145-150.
45. Herath, N.I., B.A. Leggett, and G.A. Macdonald, Review of genetic and epigenetic alterations in hepatocarcinogenesis. Journal of Gastroenterology and Hepatology, 2006; 21(1): 15-21.
46. Huttenhofer, A., RNomics: an experimental approach that identifies 201 candidates for novel, small, non-messenger RNAs in mouse. The EMBO Journal, 2001; 20(11): 2943-2953.
47. Lagos-Quintana, M., Identification of Novel Genes Coding for Small Expressed RNAs. Science, 2001; 294(5543): 853-858.
48. Kiss, T., Small Nucleolar RNAs. Cell, 2002; 109(2): 145-148.
49. Kato, M. and F.J. Slack, microRNAs: small molecules with big roles -C. elegans to human cancer. Biology of the Cell, 2008; 100(2): 71-81.
50. Kent, O.A. and J.T. Mendell, A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene, 2006; 25(46): 6188-6196.
51. Zhang, L.-H., Molecular profiling of hepatocellular carcinomas by cDNA microarray. World Journal of Gastroenterology, 2005; 11(4): 463.
52. Phizicky, E., et al., Protein analysis on a proteomic scale. Nature, 2003; 422(6928): 208-215.
53. G[illegible]rg, A., W. Weiss, and M.J. Dunn, Current two-dimensional electrophoresis technology for proteomics. Proteomics, 2004; 4(12): 3665-3685.
54. Zhang, X., et al., Mass spectrometry-based "omics" technologies in cancer diagnostics. Mass Spectrom. Rev., 2007; 26(3): 403-431.
55. Lee, I.N., et al., Identification of Human Hepatocellular Carcinoma-Related Biomarkers by Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry. J. Proteome Res., 2005; 4(6): 2062-2069.
56. Van den Bergh, G. and L. Arckens, Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Current Opinion in Biotechnology, 2004; 15(1): 38-43.
57. Yan, J.X., et al., Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics, 2002; 2(12): 1682-1698.
58. Hortin, G.L., The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome. Clinical Chemistry, 2006; 52(7): 1223-1237.
59. Rochfort, S., Metabolomics Reviewed: A New "Omics" Platform Technology for Systems Biology and Implications for Natural Products Research. J. Nat. Prod., 2005; 68(12): 1813-1820.
60. Bergquist, J., et al., Peptide mapping of proteins in human body fluids using electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Mass Spectrom. Rev., 2002; 21(1): 2-15.
61. Kim, W., et al., Comparison of proteome between hepatitis B virus-and hepatitis C virus-associated hepatocellular carcinoma. Clinical cancer research, 2003; 9(15): 5493-5500.
62. Yokoyama, Y., et al., Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics, 2004; 4(7): 2111-2116.
63. Blanc, J.-F., et al., Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics, 2005; 5(14): 3778-3789.
64. Li, C., et al., Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics, 2005; 5(4): 1125-1139.
65. Ieta, K., et al., Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. International Journal of Cancer, 2007; 121(1): 33-38.
66. Michalopoulos, G.K., Liver Regeneration. Science, 1997; 276(5309): 60-66.
67. Pardal, R., M.F. Clarke, and S.J. Morrison, Applying the principles of stem-cell biology to cancer. Nature Reviews Cancer, 2003; 3(12): 895-902.
68. Hamazaki, T., et al., Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS Letters, 2001. 497(1): 15-19.
69. Lee, K.-D., et al., In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology, 2004; 40(6): 1275-1284.
70. Lázaro, C.A., et al., Generation of hepatocytes from oval cell precursors in culture. Cancer research, 1998; 58(23): 5514-5522.
71. Lowes, K.N., et al., Oval Cell Numbers in Human Chronic Liver Diseases Are Directly Related to Disease Severity. The American Journal of Pathology, 1999; 154(2): 537-541.
72. Llovet, J.M., A. Burroughs, and J. Bruix, Hepatocellular carcinoma. The Lancet, 2003; 362(9399): 1907-1917.
73. Llovet, J., Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003; 37(2): 429-442.
74. Llovet, J.M., M. Schwartz, and V. Mazzaferro, Resection and Liver Transplantation for Hepatocellular Carcinoma. Semin Liver Dis., 2005; 25(02): 181-200.

75. Cohen, P., Protein kinases — the major drug targets of the twenty-first century? Nature Reviews Drug Discovery, 2002; 1(4): 309-315.
76. Philip, P.A., Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer. Journal of Clinical Oncology, 2005; 23(27): 6657-6663.
77. Thomas, M., et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). in ASCO Annual Meeting Proceedings, 2007.
78. O'Dwyer, P., et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. in ASCO Annual Meeting Proceedings, 2006.
79. Schwartz, J., et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. in ASCO Annual Meeting Proceedings, 2006.
80. Malka, D., et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. in ASCO Annual Meeting Proceedings, 2007.
81. Sun, W., et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. in ASCO Annual Meeting Proceedings, 2007.
82. Zhu, A.X., Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of Clinical Oncology, 2006; 24(12): 1898-1903.
83. Faivre, S., et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). in ASCO Annual Meeting Proceedings, 2007.
84. Zhu, A.X., et al., A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2007; 25(20): 213.
85. Breuhahn, K., T. Longerich, and P. Schirmacher, Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene, 2006; 25(27): 3787-3800.
86. Chiang, D.Y., et al., Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. Cancer Research, 2008; 68(16): 6779-6788.
87. Boyault, S., et al., Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007; 45(1): 42-52.
88. Farazi, P.A., et al., Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer research, 2003; 63(16): 5021-5027.